Skip to contentC
CytomX Therapeutics, Inc.
C
CTMXCytomX Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$41.46M$41.46M+76.4% vs Q1 2023 Net Income$13.79M$13.79MN/M vs Q1 2023 EPS Diluted$0.17$0.17N/M vs Q1 2023 Operating Income$11,657,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CytomX Therapeutics, Inc. · CIK 1501989 · Engraved from SEC EDGAR
Free Cash Flowderived-$26,160,000N/M Margins · derivedOperating margin28.1%+52.2 pt vs Q1 2023
Net margin33.3%+47.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end